The high dose of Eli Lilly’s retatrutide led to an average 28.7% loss in body weight measured at 68 weeks. These Phase 3 results are the first from the experimental obesity drug’s broad clinical trial program, which is on track to yield seven data readouts in the coming year.
Eli Lilly’s retatrutide led to an average weight reduction of 24.2%, or 58 pounds, after 48 weeks of treatment in Phase 2 testing. Based on these results, Lilly now plans a comprehensive Phase 3 program that will evaluate the once-weekly injectable drug in weight reduction as well as various complications of obesity.
AI-native tax firm Gelt combines top human tax experts with AI to help physicians and healthcare practices use data-driven tax strategies to lower liabilities, improve profitability, and future-proof their finances.